Radiopharm Theranostics logo
Radiopharm Theranostics
RADX | NASDAQ
Chart Builder DCF Calculator
$0.72
-$0.04 (-5.26%)
At close: Nov 16, 2026, 3:59 PM ET
$0.70
-$0.02 (-2.78%)
After-hours: Nov 16, 2026, 7:58 PM ET

Radiopharm Theranostics Company Profile

Company profile explained

Company Profile

Radiopharm Theranostics Limited, an Australian company established in Carlton in 2021, specializes in the research and development of cutting-edge radiopharmaceutical treatments. Their mission is to address critical gaps in healthcare by creating products for both diagnostic imaging and therapeutic intervention across a spectrum of challenging medical conditions. The company's diverse pipeline features: RAD 204, designed to target PD-L1 for non-small cell lung cancer; RAD 202, aimed at HER2 for breast cancer and other solid tumor types; and two avß6 integrin-targeting agents, RAD 301 (a diagnostic tool for pancreatic ductal adenocarcinoma) and RAD 302 (a therapeutic agent for various cancers). Other significant developments include RAD 101 and RAD 102 for brain metastases, RAD 402 for advanced prostate cancer, and RV01 for multiple solid tumors. To accelerate the clinical progression of its radiopharmaceutical assets, Radiopharm Theranostics maintains a strategic partnership with Lantheus Holdings, Inc.

Key Executives

Name Position
Riccardo Canevari MD, Chief Executive Officer & Director
Aaron Laurita Chief Financial Officer
Amritha Sushil Joint Company Secretary
Dimitris Voliotis Chief Medical Officer
Hitesh Goel Head of Project Management
Nathan Jong Joint Company Secretary
Paul Edward-Alexander Hopper FAICD Founder & Executive Chairman

Latest SEC Filings

Date Type Title
Oct 30, 2026 6-K Filing
Oct 27, 2026 4 Filing
Oct 27, 2026 6-K Filing
Oct 26, 2026 6-K Filing
Oct 20, 2026 6-K Filing
Oct 14, 2026 SC 13G Statement of acquisition of beneficial ownership b...
Oct 05, 2026 6-K Filing
Oct 01, 2026 6-K Filing
Sep 30, 2026 20-F Filing
Sep 30, 2026 6-K Filing
View All SEC Filings ➞
Radiopharm Theranostics
Radiopharm Theranostics logo
Country Australia
IPO Date Dec 5, 2024
Industry Biotechnology
Sector Healthcare
Employees 14
CEO Riccardo Canevari

Contact Details

62 Lygon Street Carlton, VIC 3053 Australia

Stock Details

Ticker Symbol RADX
Exchange NASDAQ
Fiscal Year July - June
Reporting Currency USD
CIK Code 0001949257
CUSIP Number 75041J101
ISIN Number US75041J1016
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.